Home News Mitsui Chemicals Agrees to Buy JSR in a 1,840 Billion Yen Transaction

Mitsui Chemicals Agrees to Buy JSR in a 1,840 Billion Yen Transaction

32
0
A chemical processing plant with distillation columns and storage silos

Mitsui Chemicals has signed a share purchase agreement to acquire the semiconductor materials maker JSR Corporation from funds managed by Japan Investment Corporation, in a transaction the buyer values at 1,840 billion yen. The agreement was disclosed on 9 November 2026.

The issuer breaks the total into 1,392.1 billion yen of equity and 447.9 billion yen of interest bearing debt and other items. The Development Bank of Japan is providing 200 billion yen of the equity. The buyer is acquiring the JSR common shares held by the seller funds, together with two classes of preferred shares, and expects to hold all of the voting rights once the transaction closes.

Completion is targeted for the second half of the financial year ending March 2028 and remains subject to competition and foreign investment clearances. Nothing has closed.

Why the state is in the equity

The presence of a government backed lender in the equity of a chemicals acquisition is the part of this transaction that carries policy weight rather than financial weight. Photoresists and the related lithography materials that JSR supplies are a narrow chokepoint in semiconductor manufacturing, and the number of firms capable of qualifying new generations of them is small. Japan has spent several years moving to secure domestic control of precisely these positions, and a 200 billion yen state participation is consistent with that rather than with an ordinary co investment.

What the buyer is actually buying

The acquirer places the semiconductor materials business inside its own information and communications technology portfolio and treats JSR's life sciences contract research and manufacturing arm as non core. That framing is the clearest signal available about what happens after completion, and executives tracking the sector should expect the life sciences assets to be reviewed separately rather than integrated.

Two points of confusion are worth closing. This is not the earlier take private of JSR by that same state backed investor, which created the present sellers. And the dollar figures in circulation are press conversions; the issuer states the transaction only in yen.